Shaunak Navalkissoor

Nuclear medicine theragnostics: walk before you run

Theragnostic nuclear medicine is a much discussed topic in nuclear medicine and is currently discussed and debated in clinical oncology with great interest and optimism. Radionuclide theragnostics generally pairs diagnostic biomarkers with radiolabelled therapeutic agents that share a specific target within the diseased cells or tissues. The clinical indications are expanding, with evolving evidence. Incorporating […]

Dr Gopinath Gnanasegaran, Dr Shaunak Navalkissoor

Royal Free London NHS Foundation Trust

Read Article

Clinical implications of FDG PETCT in cancer of unknown primaries

Cancer of unknown primary (CUP) has an incidence of 3.3% in the UK but this is falling, largely due to improvement in diagnostics, enabling underlying pathology to be identified and treated, therefore improving survival outcomes. F-18 FDG PETCT is increasingly being used to investigate for malignancy in patients in whom initial tests have proven inconclusive […]

Emily Vaughan, Shaunak Navalkissoor

Royal Free London NHS Foundation Trust

Read Article

Stay up to date with
RAD Magazine

Sign up for our newsletter.

We care about your data. Read our privacy policy.